Showing results (51-60 of 100) with videos related to
Sort By:
Pageof 10
Breast Cancer Research : BCR|August 24, 2021
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trialPatrick Neven, Hope S Rugo, Sara M Tolaney, et al.Radiology. Imaging Cancer|April 5, 2024
Long-term Mammography Screening Trends and Predictors of Return to Screening after the COVID-19 Pandemic: Results from a Statewide RegistryBrian L Sprague, Sarah A Nowak, Thomas P Ahern, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31Edith A Perez, Edward H Romond, Vera J Suman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant TrialEdith A Perez, Vera J Suman, Nancy E Davidson, et al.Optics Letters|March 22, 2007
Image-guided optical spectroscopy provides molecular-specific information in vivo: MRI-guided spectroscopy of breast cancer hemoglobin, water, and scatterer sizeColin M Carpenter, Brian W Pogue, Shudong Jiang, et al.Radiology|March 17, 2011
Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?Marius G Pakalniskis, Wendy A Wells, Mary C Schwab, et al.The Lancet. Oncology|February 19, 2013
Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trialJohn Fr Robertson, Jean-Marc Ferrero, Hugues Bourgeois, et al.Radiology|June 11, 2009
Evaluation of breast tumor response to neoadjuvant chemotherapy with tomographic diffuse optical spectroscopy: case studies of tumor region-of-interest changesShudong Jiang, Brian W Pogue, Colin M Carpenter, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERsSara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.The Oncologist|February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs RegistryDebu Tripathy, Adam Brufsky, Melody Cobleigh, et al.Pageof 10